Moreover, STAU2‐ASO was developed as the first inhibitor targeting STAU2, demonstrating anti‐tumor activity both in vitro and in vivo and providing a promising novel therapeutic strategy for pancreatic cancer treatment. This evidence concerns the gene STAU2 and familial pancreatic carcinoma.